---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Fresh frozen plasma and other measures"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Fresh frozen plasma and other measures. Topics: Solvent detergent-treated plasma and fresh frozen plasma: third-line on-demand treatment, Fresh frozen plasma: US guideline fallback and risk of worsening, Frozen plasma: International/Canadian guideline recommendation and access delays, Fresh frozen or solvent detergent plasma in children: pediatric guideline, and 4 further topics. 8 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/fresh-frozen-plasma-and-other-measures"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Fresh frozen plasma and other measures

<a id="heading-2.2.2.1.5"></a>

## 2.2.2.1.5 Fresh Frozen Plasma and Other Measures

<a id="topic-2.2.2.1.5-1"></a>

### Solvent detergent-treated plasma and fresh frozen plasma: third-line on-demand treatment

> “If IV C1-INH, icatibant, sebetralstat or ecallantide is unavailable, solvent detergent-treated plasma (SDP) or FFP may be considered, provided that a safe and reliable supply of these blood products can be ensured.”
> “We recommend SDP/FFP as third-line treatment, with SDP preferred over FFP if available due to a lower risk of viral transmission.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “Where these first-line therapies are not available, attacks should be treated with solvent detergent-treated plasma (SDP). If SDP is not available, attacks should be treated with fresh frozen plasma (FFP), where safe supply is available.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

<a id="topic-2.2.2.1.5-2"></a>

### Fresh frozen plasma: US guideline fallback and risk of worsening

> “treat HAE attacks if none of the FDA-approved on-demand medications are available.”
> “The efficacy of FFP has not been studied in randomized trials, and there are anecdotal reports of HAE symptoms precipitously worsening after FFP administration”

Source: [Busse et al. (2021)](https://www.haea.org/assets/img/TreatmentGuidelines040321.pdf)

<a id="topic-2.2.2.1.5-3"></a>

### Frozen plasma: International/Canadian guideline recommendation and access delays

> “Frozen plasma could be used for acute treatment of attacks if other recommended therapies are not available.”
> “Additionally, FP contains substrates that may promote bradykinin generation, potentially worsening angioedema attacks.”
> “Both FP and SDP are only available for in-hospital use, and there can be significant delays”
> “Therefore, FP use should be limited to life-threatening or severely painful attacks when no other HAE-specific therapies are accessible.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.1.5-4"></a>

### Fresh frozen or solvent detergent plasma in children: pediatric guideline

> “We suggest, when none of the first‐line treatment options are available, using fresh frozen or solvent detergent plasma for acute treatment of angioedema attacks involving the upper airway, gastrointestinal tract, neck, or face in pediatric patients with hereditary angioedema due to C1 inhibitor deficiency.”
> “These agents are associated with a risk of anaphylactic reaction and transmission of blood‐borne infections”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

<a id="topic-2.2.2.1.5-5"></a>

### Antifibrinolytics and attenuated androgens: not recommended for acute attacks

> “Using antifibrinolytics (such as tranexamic acid) or attenuated androgens (such as danazol) for ODT is discouraged because of a lack of benefit.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “We advise against the use of antifibrinolytics (eg, tranexamic acid) or androgens (eg, danazol) for on-demand treatment of HAE attacks”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

> “Attenuated androgens and tranexamic acid should not be used for the acute treatment of attacks.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.1.5-6"></a>

### Antihistamines, corticosteroids, and epinephrine: ineffective for bradykinin-mediated attacks

> “Antihistamines, corticosteroids, and epinephrine are ineffective for BK-AE and should not be used, as their use may delay the administration of specific treatments for BK-AE.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “specifically avoid therapies that lack supporting evidence, such as antihistamines, corticosteroids, or epinephrine, which treat mast cell–mediated but not bradykinin-mediated angioedema.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.1.5-7"></a>

### Supportive care when effective on-demand treatment is not available

> “IV fluids, antiemetics, narcotic pain medication, or intubation”

Source: [Busse et al. (2021)](https://www.haea.org/assets/img/TreatmentGuidelines040321.pdf)

<a id="topic-2.2.2.1.5-8"></a>

### Upper airway involvement and airway management: guideline recommendations

> “We recommend that in the case of upper airway swelling, ODT should be given as early as possible, and patients should seek emergency care.”
> “We recommend that airway interventions (intubation, cricothyroidotomy, or tracheotomy) be promptly considered during the initial evaluation of patients presenting with signs of upper airway involvement.”
> “If intubation is indicated but proves difficult or impossible, an emergency cricothyrotomy or tracheotomy should be performed without delay.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “We recommend that intubation or surgical airway intervention is considered early in progressive upper airway edema.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

> “We recommend that upper airway, facial, and neck edema should always be treated. In case of upper airway edema, pediatric patients with hereditary angioedema should also have an emergency referral to a hospital where airway management is available.”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
